RT Journal Article
T1 More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments
A1 Sekulovic, L. Kandolf
A1 Peris, K.
A1 Hauschild, A.
A1 Stratigos, A.
A1 Grob, J. -J.
A1 Nathan, P.
A1 Dummer, R.
A1 Forsea, A. -M.
A1 Hoeller, C.
A1 Gogas, H.
A1 Demidov, L.
A1 Lebbe, C.
A1 Blank, C.
A1 Olah, J.
A1 Bastholt, L.
A1 Herceg, D.
A1 Neyns, B.
A1 Vieira, R.
A1 Hansson, J.
A1 Rutkowski, P.
A1 Krajsova, I.
A1 Bylaite-Bucinskiene, M.
A1 Zalaudek, I.
A1 Maric-Brozic, J.
A1 Babovic, N.
A1 Banjin, M.
A1 Putnik, K.
A1 Weinlich, G.
A1 Todorovic, V.
A1 Kirov, K.
A1 Ocvirk, J.
A1 Zhukavets, A.
A1 Kukushkina, M.
A1 De La Cruz Merino, L.
A1 Ymeri, A.
A1 Risteski, M.
A1 Garbe, C.
K1 Access
K1 Innovative medicines
K1 Metastatic melanoma
K1 Treatment
K1 Immuno oncology
K1 Targeted therapy
K1 Health expenditure per capita
K1 Human development index
K1 Health-care
K1 Malignant-melanoma
K1 Cancer incidence
K1 Disparities
K1 Mortality
K1 Medicines
K1 Diagnosis
K1 Survival
K1 Reimbursement
K1 Union
AB Background: Despite the efficacy of innovative treatments for metastatic melanoma, their high costs has led to disparities in cancer care among different European countries. We analysed the availability of these innovative therapies in Europe and estimated the number of patients without access to first-line recommended treatment per current guidelines of professional entities such as the European Society for Medical Oncology (ESMO), the European Organisation for Research and Treatment of Cancer (EORTC), the European Association of Dermato-Oncology (EADO), and European Dermatology Forum (EDF).Materials and methods: Web-based online survey was conducted in 30 European countries with questions about the treatment schedules from 1st May 2015 to 1st May 2016: number of metastatic melanoma patients, registration and reimbursement of innovative medicines (updated data, as of 1st October 2016), percentage of patients treated and availability of clinical studies and compassionate-use programmes.Results: The recommended BRAF inhibitor (BRAFi) + MEK inhibitor (MEKi) combination was both registered and fully reimbursed in 9/30 (30%) countries, and in 13/30 (43%) (all from Eastern Europe) not reimbursed. First-line immunotherapy with anti-PD1 antibodies was registered and fully reimbursed in 14/30 (47%) countries, while in 13/30 (43%) (all from Eastern Europe) not reimbursed. It was estimated that in Europe 19,600 patients with metastatic melanoma are treated, and 5238 (27%) do not have access to recommended first-line therapy. Significant correlation was found between human development index (HDI, UNDP report 2015), (r = 0.662; p
PB Elsevier sci ltd
SN 0959-8049
YR 2017
FD 2017-04-01
LK http://hdl.handle.net/10668/18767
UL http://hdl.handle.net/10668/18767
LA en
DS RISalud
RD Apr 9, 2025